Submit Manuscript  

Article Details


Anti-Proliferative Compounds for the Prevention of Restenosis: Anti-Restenotic Mechanisms of Paclitaxel Action

[ Vol. 16 , Issue. 36 ]

Author(s):

Mark C. Lavigne, Michael J. Eppihimer, Ruth Cheng and James J. Barry   Pages 3989 - 4001 ( 13 )

Keywords:

Drug eluting stent (DES), local drug delivery, biostable, bioabsorbable, drug delivery, stent, Restenosis, Paclitaxel Action, Coronary artery disease, myocardium, thrombosis, congestive heart failure, drug-eluting stent, Angioplasty, vascular smooth muscle, endothelial, balloon, diabetes, Paclitaxel, Cardiovascular disease, bare metal stents, anti-cancer drugs, neutrophils, platelet-derived growth factor, CCR2, MCP-1, ICAM-1, GPIb, active pharmaceutical ingredient, BiodVysio stents, (“M”)-phase, TAXOL, Paclitaxel-induced apoptosis, DNA fragmentation, neointimal hyperplasia, MHC II, TGF-, SMAD3, diabetics, rosiglitazone, sirolimus

Affiliation:

Preclinical Sciences, Boston Scientific Corporation, One Boston Scientific Place, Natick, MA 01760.



Read Full-Text article